AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02206867 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira
Description: Anti-inflammatory agents
Study NCT02399319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Fixator
Description: Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
Study NCT02399319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Symphyseal Plate
Description: A plate that spans across the symphysis to maintain reduction and stability.
Study NCT00252499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: PPAR-alpha agonist, reduces triglycerides
Study NCT01480375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartbx™ system.
Description: The SmartBx™ system semi-automated downloads the biopsy cores from the biopsy needle onto a designated cassette which integrates into the routine pathology lab processing. The core is downloaded in an oriented and straightened fashion while preserving core fragments in its original locations relative to the needle notch.
Study NCT04131257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Continuum of Care
Description: This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
Study NCT04131257 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-led Continuum of Care
Description: This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
Study NCT03041090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lucerno ID (identification) System
Description: The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.
Study NCT03053414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (ergocalciferol and/ or cholecalciferol)
Description: To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.
Study NCT00252499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for rosiglitazone
Description: placebo tablets that are matched to look like rosiglitazone
Study NCT00252499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for rosiglitazone
Description: placebo tablets that are matched to look like rosiglitazone
Study NCT00252499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for fenofibrate
Description: placebo matched to look like fenofibrate tablets
Study NCT01673399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atosiban
Description: Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.
Study NCT01673399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00853528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
Study NCT00252499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for fenofibrate
Description: placebo matched to look like fenofibrate tablets
Study NCT00383643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zolpidem tartrate
Study NCT00383643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium oxybate
Study NCT00383643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebos
Study NCT00383643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebos
Study NCT04410666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green Tea mouthwash
Description: an infusion at 13%, with 13 g of green tea (commercially divided) in 100 ml of saline solution, at a temperature of approximately 90 ° C, in sterile glass containers.~Each application was 10 ml. applied for 1 minute.
Study NCT04410666 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Mouthwash
Description: distilled water
Study NCT01556048 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Activation
Description: Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, \& Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
Study NCT01556048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, \& Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
Study NCT03894969 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E
Description: 2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
Study NCT03894969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E
Description: 2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
Study NCT04615728 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic or open appendicectomy
Description: Laparoscopic/open appendicectomy versus conservative management with antibiotic therapy with or without image-guided drainage of appendicular abscess/collection
Study NCT02255240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
Study NCT03010059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral suspension formulation)
Description: Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.
Study NCT01453114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
Study NCT03676933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS107E
Study NCT03676933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT03676933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Butyrate 0.1% Cream
Description: Steroid taken topically once a day
Study NCT03676933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone Butyrate 0.1% Cream
Description: Steroid taken topically once a day
Study NCT01905384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covered Self-expanding metal biliary stents (C-SEMS)
Description: Used for palliation of inoperable malignant distal bile duct obstruction.
Study NCT01905384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered Self-expanding metal biliary stents (U-SEMS)
Description: Used for palliation of inoperable malignant distal bile duct obstructions.
Study NCT00775151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine 10 mg tablet
Study NCT00775151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 10 mg tablet
Study NCT03804944 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Focal Radiation therapy
Description: Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
Study NCT03804944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab (200mg IV for 30 minutes
Description: Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
Study NCT03804944 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CDX-301
Description: Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
Study NCT03579589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex vs Neostigmine
Description: Patients will be randomized into either Sugammadex or Neostigmine neuromuscular blockade reversal.
Study NCT03894969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
Description: 2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
Study NCT00853528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion tensor imaging
Description: prior to initiating CyberKnife radiosurgery, at 6 weeks after CyberKnife therapy, and at 6 months after CyberKnife therapy
Study NCT00853528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging
Description: prior to CyberKnife, at 6 weeks, and 3 months after CyberKnife?, every 3 months for the first year, and every 6 months thereafter
Study NCT00853528 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypo-fractionated SRS
Description: two to three consecutive daily sessions within one week for 3 cohorts- Cohort 1 = 21 Gy; Cohort 2 = 24 Gy; Cohort 3 = 27 Gy
Study NCT00853528 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: single-fraction SRS
Description: two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy
Study NCT02477254 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vaccination
Description: A quadrivalent HPV vaccine
Study NCT03862469 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Individualized laboratory test
Description: Laboratory test administered between 6 and 2 days prior to the subsequent menstrual cycle.
Study NCT03028480 — intervention group
Intervention type: DRUG
Intervention: NUCALA Injection
Description: Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
Study NCT02536300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablet administered orally
Study NCT04129372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Foods Take Time
Description: New Foods Take Time is a series of 5 classroom lessons focused on increasing children's willingness to try fruits and vegetables.
Study NCT03376659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 750mg IV q2 weeks
Study NCT03376659 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301
Description: MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c.
Study NCT03376659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg orally twice a day, Monday - Friday Weekly
Study NCT02049307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan 100mg daily
Study NCT02049307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Study NCT04226274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REN001
Description: Once daily for 12 weeks
Study NCT00680745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
Study NCT00680745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
Study NCT00680745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
Study NCT00680745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Study NCT02654431 — intervention group
Intervention type: PROCEDURE
Intervention: Breast Cancer patient
Description: Samples
Study NCT02654431 — intervention group
Intervention type: PROCEDURE
Intervention: Cancer patients
Description: Samples
Study NCT00680745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin hydrochloride
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Study NCT00680745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone hydrochloride
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Study NCT03376659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg IV q2weeks
Study NCT04365959 — intervention group
Intervention type: PROCEDURE
Intervention: Prone position
Description: The objective of the study is to value the ability of the prone position to increase the oxygenation of the patient with SARS-cov-2 pneumonia as a lung recruitment index; the PP also prevents the need for intubation and the consequent risk deriving from the procedure itself and from the predisposition to develop superinfections (VAP).
Study NCT01353274 — intervention group
Intervention type: DRUG
Intervention: Micamlo
Description: Telmisartan plus Amlodipine T40/A5
Study NCT03862898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar stabilization exercises
Description: Patients performed exercises to stabilize and strengthen paravertebral muscles. Three sets of ten repetitions with a minute break between each.
Study NCT03862898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Description: Patients performed exercises to stabilize and strengthen paravertebral muscles. Three sets of ten repetitions with a minute break between each.
Study NCT02430454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased cognitive load
Description: simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
Study NCT02431767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PENNVAX®-GP HIV-1 DNA vaccine
Description: Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
Study NCT02431767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-12 (IL-12) DNA adjuvant
Description: Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
Study NCT02431767 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
Study NCT03675321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Auricular Neurostimulation
Description: Active auricular neurostimulation for 4 weeks. Subjects in Active group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy.
Study NCT03675321 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Auricular Neurostimulation
Description: Sham auricular neurostimulation for 4 weeks with identical device as the active but lacking the electrical charge.~Subjects in Sham group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy.
Study NCT02808234 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: One or two level lumbar interbody fusion surgery
Description: One or two level lumbar interbody fusion surgery with allograft derived from human amnion and amniotic fluid.
Study NCT02808234 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nucel
Description: Allograft derived from human amnion and amniotic fluid
Study NCT02177825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: oral administration
Study NCT00856687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03893787
Description: Oral, two doses 12 hours apart
Study NCT00856687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, two doses 12 hours apart
Study NCT00856687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Oral, two doses 12 hours apart
Study NCT00851578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN
Description: WATCHMAN LAA Closure Device
Study NCT00648674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apligraf
Description: Applied at Day 0, possible re-application at Week 6
Study NCT02441374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tubular mesh.
Description: Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.
Study NCT02441374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical kinesiotherapy.
Description: Applying classical kinesiotherapy in upper limb post stroke.
Study NCT00681941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (Renvela®)
Description: Sevelamer Carbonate Tablets Dosed Three Times A Day
Study NCT00680745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone hydrochloride
Description: rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
Study NCT03010059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575 (oral tablet formulation )
Description: Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.
Study NCT03866239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by intravenous (IV) infusion as either a split or single dose approximately 2 weeks before Cycle 1, Day 1 (cycle = 21 days).
Study NCT03866239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
Study NCT03866239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cibisatamab
Description: Cibisatamab will be administered at a fixed dose of 100 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
Study NCT03041961 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.